Xlumena

Xlumena

Designed minimally invasive endoscopic tools for therapeutic and diagnostic procedures in gastroenterology. Acquired by Boston Scientific in 2015.

ViaCyte

ViaCyte

Develops cell replacement therapies for diabetes. ViaCyte was acquired by Vertex Pharmaceuticals in 2022.

True North Therapeutics

True North Therapeutics

Focused on developing treatments for rare diseases mediated by the complement system. Acquired by Bioverativ in 2017.